ARCHIVES

Gleevec For KIT-positive Tumors Shows 92 Percent Overall Survival

This article is from The Cancer Letter archive.

Vol. 34 No. 7 | July 29, 2011

Download PDF Visit The Full Archive

Related Articles

FDA Approves Votrient For Renal Cell Carcinoma

October 23, 2009

In Brief: Salmon, Fidler Head ASCO, AACR; Durant, Pardee Presidents Elect; Namovicz, Other AOs Promoted

May 25, 1984

Conte To Introduce Bill To Stem Loss Of NIH “Superstars”

March 31, 1989

In Brief: The Anatomy Of An Administrative Nightmare: How NIH Spent $518 Million In One Day

October 23, 1992

NIH Sets Tuition Cost Policy For NRSA Grants

February 9, 1996

Clinical Trials Approved By NCI

November 28, 2003